nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Cell based cancer vaccines: Regulatory and commercial development
|
Copier, John |
|
2007 |
25 |
S2 |
p. B35-B46 nvt p. |
artikel |
2 |
Clinical proteomics: Discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches—A prostate cancer perspective
|
Matharoo-Ball, Balwir |
|
2007 |
25 |
S2 |
p. B110-B121 nvt p. |
artikel |
3 |
Dendritic cells for active immunotherapy: Optimizing design and manufacture in order to develop commercially and clinically viable products
|
Nicolette, C.A. |
|
2007 |
25 |
S2 |
p. B47-B60 nvt p. |
artikel |
4 |
Editorial Board
|
|
|
2007 |
25 |
S2 |
p. CO2- 1 p. |
artikel |
5 |
Enhancing cancer vaccines with immunomodulators
|
Berinstein, Neil L. |
|
2007 |
25 |
S2 |
p. B72-B88 nvt p. |
artikel |
6 |
Enhancing efficacy of therapeutic vaccinations by combination with other modalities
|
Gulley, James L. |
|
2007 |
25 |
S2 |
p. B89-B96 nvt p. |
artikel |
7 |
GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development
|
Brichard, Vincent G. |
|
2007 |
25 |
S2 |
p. B61-B71 nvt p. |
artikel |
8 |
Lessons from randomized phase III studies with active cancer immunotherapies – Outcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC)
|
Finke, Lothar H. |
|
2007 |
25 |
S2 |
p. B97-B109 nvt p. |
artikel |
9 |
Perspectives on the development of a therapeutic HER-2 cancer vaccine
|
Renard, Valéry |
|
2007 |
25 |
S2 |
p. B17-B23 nvt p. |
artikel |
10 |
Plasmid DNA and viral vector-based vaccines for the treatment of cancer
|
Anderson, Richard J. |
|
2007 |
25 |
S2 |
p. B24-B34 nvt p. |
artikel |
11 |
Therapeutic cancer vaccines
|
Ward, Stephen |
|
2007 |
25 |
S2 |
p. B1-B3 nvt p. |
artikel |
12 |
Vaccine therapy for melanoma: Current status and future directions
|
Terando, Alicia M. |
|
2007 |
25 |
S2 |
p. B4-B16 nvt p. |
artikel |